IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders spotthedot2025-11-02T17:48:14+00:00June 29th, 2022| Read More
IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference spotthedot2025-11-02T17:48:14+00:00June 1st, 2022| Read More
IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology spotthedot2025-11-02T17:48:14+00:00December 17th, 2021| Read More
CEO Damon Burrows featured on OIS Podcast spotthedot2025-11-02T17:48:14+00:00November 16th, 2021| Read More
IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury spotthedot2025-11-02T17:48:14+00:00October 28th, 2021| Read More
IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer spotthedot2025-11-02T17:48:14+00:00July 27th, 2021| Read More
IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain spotthedot2025-11-02T17:48:15+00:00January 7th, 2021| Read More
IACTA Pharmaceuticals featured in Orange County Business Journal’s Startups and Innovations section spotthedot2025-11-02T17:48:15+00:00August 10th, 2020| Read More
IACTA Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments spotthedot2025-11-02T17:48:15+00:00July 30th, 2020| Read More
New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia spotthedot2025-11-02T17:48:15+00:00July 28th, 2020| Read More
Connect with us